Literature DB >> 22865267

Memory T cells are uniquely resistant to melanoma-induced suppression.

Lucy Wentworth1, Justin V Meyers, Sheeba Alam, Andrew J Russ, M Suresh, Clifford S Cho.   

Abstract

We have previously observed that in vivo exposure to growing melanoma tumors fundamentally alters activated T cell homeostasis by suppressing the ability of naïve T cells to undergo antigen-driven proliferative expansion. We hypothesized that exposure of T cells in later stages of differentiation to melanoma would have similar suppressive consequences. C57BL/6 mice were inoculated with media or syngeneic B16F10 melanoma tumors 8 or 60 days after infection with lymphocytic choriomeningitis virus (LCMV), and splenic populations of LCMV-specific T cells were quantified using flow cytometry 18 days after tumor inoculation. Inoculation with melanoma on post-infection day 8 potentiated the contraction of previously activated T cells. This enhanced contraction was associated with increased apoptotic susceptibility among T cells from tumor-bearing mice. In contrast, inoculation with melanoma on post-infection day 60 did not affect the ability of previously established memory T cells to maintain themselves in stable numbers. In addition, the ability of previously established memory T cells to respond to LCMV challenge was unaffected by melanoma. Following adoptive transfer into melanoma-bearing mice, tumor-specific memory T cells were significantly more effective at controlling melanoma growth than equivalent numbers of tumor-specific effector T cells. These observations suggest that memory T cells are uniquely resistant to suppressive influences exerted by melanoma on activated T cell homeostasis; these findings may have implications for T cell-based cancer immunotherapy.

Entities:  

Mesh:

Year:  2012        PMID: 22865267      PMCID: PMC4550291          DOI: 10.1007/s00262-012-1326-1

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  27 in total

1.  Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor.

Authors:  Nikhil S Joshi; Weiguo Cui; Anmol Chandele; Heung Kyu Lee; David R Urso; James Hagman; Laurent Gapin; Susan M Kaech
Journal:  Immunity       Date:  2007-08       Impact factor: 31.745

Review 2.  Homeostasis of memory T cells.

Authors:  Charles D Surh; Onur Boyman; Jared F Purton; Jonathan Sprent
Journal:  Immunol Rev       Date:  2006-06       Impact factor: 12.988

3.  Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection.

Authors:  K Murali-Krishna; J D Altman; M Suresh; D J Sourdive; A J Zajac; J D Miller; J Slansky; R Ahmed
Journal:  Immunity       Date:  1998-02       Impact factor: 31.745

4.  Regulation of memory CD8 T-cell differentiation by cyclin-dependent kinase inhibitor p27Kip1.

Authors:  Anju Singh; Anna Jatzek; Erin Hemmila Plisch; Rajini Srinivasan; John Svaren; M Suresh
Journal:  Mol Cell Biol       Date:  2010-08-30       Impact factor: 4.272

5.  Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.

Authors:  Christopher A Klebanoff; Luca Gattinoni; Parizad Torabi-Parizi; Keith Kerstann; Adela R Cardones; Steven E Finkelstein; Douglas C Palmer; Paul A Antony; Sam T Hwang; Steven A Rosenberg; Thomas A Waldmann; Nicholas P Restifo
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-24       Impact factor: 11.205

6.  CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.

Authors:  Mark E Dudley; Colin A Gross; Michelle M Langhan; Marcos R Garcia; Richard M Sherry; James C Yang; Giao Q Phan; Udai S Kammula; Marybeth S Hughes; Deborah E Citrin; Nicholas P Restifo; John R Wunderlich; Peter A Prieto; Jenny J Hong; Russell C Langan; Daniel A Zlott; Kathleen E Morton; Donald E White; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2010-07-28       Impact factor: 12.531

Review 7.  The three Es of cancer immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

Review 8.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

9.  Co-expression of nuclear and cytoplasmic HMGB1 is inversely associated with infiltration of CD45RO+ T cells and prognosis in patients with stage IIIB colon cancer.

Authors:  Rui-Qing Peng; Xiao-Jun Wu; Ya Ding; Chun-Yan Li; Xing-Juan Yu; Xing Zhang; Zhi-Zhong Pan; De-Sen Wan; Li-Ming Zheng; Yi-Xin Zeng; Xiao-Shi Zhang
Journal:  BMC Cancer       Date:  2010-09-16       Impact factor: 4.430

Review 10.  Systematic review of medical treatment in melanoma: current status and future prospects.

Authors:  Claus Garbe; Thomas K Eigentler; Ulrich Keilholz; Axel Hauschild; John M Kirkwood
Journal:  Oncologist       Date:  2011-01-06
View more
  5 in total

1.  Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.

Authors:  Amanda Contreras; Siddhartha Sen; Andrew J Tatar; David A Mahvi; Justin V Meyers; Prakrithi Srinand; Marulasiddappa Suresh; Clifford S Cho
Journal:  Cancer Immunol Immunother       Date:  2016-03-24       Impact factor: 6.968

2.  Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.

Authors:  David A Mahvi; Justin V Meyers; Andrew J Tatar; Amanda Contreras; Marulasiddappa Suresh; Glen E Leverson; Siddhartha Sen; Clifford S Cho
Journal:  J Immunother       Date:  2015 Feb-Mar       Impact factor: 4.456

Review 3.  The ER-Mitochondria Interface as a Dynamic Hub for T Cell Efficacy in Solid Tumors.

Authors:  Elizabeth G Hunt; Alex M Andrews; Sydney R Larsen; Jessica E Thaxton
Journal:  Front Cell Dev Biol       Date:  2022-04-27

4.  Co-transfer of tumor-specific effector and memory CD8+ T cells enhances the efficacy of adoptive melanoma immunotherapy in a mouse model.

Authors:  Amanda Contreras; Megan V Beems; Andrew J Tatar; Siddhartha Sen; Prakrithi Srinand; M Suresh; Tahra K Luther; Clifford S Cho
Journal:  J Immunother Cancer       Date:  2018-05-29       Impact factor: 13.751

5.  Non-thermal histotripsy tumor ablation promotes abscopal immune responses that enhance cancer immunotherapy.

Authors:  Shibin Qu; Tejaswi Worlikar; Amy E Felsted; Anutosh Ganguly; Megan V Beems; Ryan Hubbard; Ashley L Pepple; Alicia A Kevelin; Hannah Garavaglia; Joe Dib; Mariam Toma; Hai Huang; Allan Tsung; Zhen Xu; Clifford Suhyun Cho
Journal:  J Immunother Cancer       Date:  2020-01       Impact factor: 13.751

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.